• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Kineta Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    9/19/24 9:21:01 AM ET
    $KA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KA alert in real time by email
    8-K
    0001445283falseKINETA, INC./DENASDAQ00014452832024-09-172024-09-17

    UNITED STATES

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): September 17, 2024

     

     

     

    KINETA, INC.

     

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware

    001-37695

    20-8436652

    (State or other jurisdiction

    (Commission

    (IRS Employer

    of incorporation)

    File Number)

    Identification No.)

    7683 SE 27th Street, Suite 481

     

     

    Mercer Island, WA

     

    98040

    (Address of principal executive offices)

     

    (Zip Code)

     

    Registrant’s telephone number, including area code: (206) 378-0400

     

    Not Applicable

     

    (Former name or former address, if changed since last report)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

     

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

     

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

     

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

     

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

    Trading

    Name of each exchange

     

     

    Symbol(s)

    on which registered

     

    Common Stock, par value $0.001 per share

     

    KA

     

    The Nasdaq Capital Market

     

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     


     

     

    Item 3.01

    Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    As previously disclosed on September 10, 2024, Kineta, Inc. (the “Company”) received a determination letter (the “Letter”) from the Nasdaq Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that after reviewing the materials submitted by the Company, the Staff had determined to deny the Company’s request for continued listing on The Nasdaq Capital Market due to the Company’s lack of compliance with Nasdaq Listing Rules 5550(a)(2) and 5550(b)(1). In the Letter, the Staff also notified the Company that trading of its securities would be suspended and the securities would be removed from listing and registration on Nasdaq unless the Company requested an appeal of Nasdaq’s determination by September 17, 2024. The Company did not appeal the determination, and therefore, on September 18, 2024, the Staff informed the Company that the Company’s common stock, par value $0.001 per share (“Common Stock”), will be suspended from trading on The Nasdaq Capital Market at the opening of business on September 19, 2024. A Form 25-NSE will be filed with the Securities and Exchange Commission by Nasdaq. The trading of the Common Stock will be suspended until delisting which will become effective 10 days after the Form 25-NSE is filed. Following the delisting of its common shares from The Nasdaq Capital Market, the Company will continue to be a reporting company under the Securities Exchange Act of 1934. It is expected that Common Stock will commence trading on the OTC Markets Group platform at the open of trading on September 19, 2024 under the symbol “KA.” Quotes and related information will be available at www.otcmarkets.com.


     

     

     


     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: September 19, 2024

     

    Kineta, Inc.

     

    By:

    /s/ Craig Philips

    Name:

    Craig Philips

    Title:

    President

     

     


    Get the next $KA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $KA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors

      Kineta has completed enrollment in the monotherapy cohorts of the Phase 1 VISTA-101 clinical trial. The ongoing Phase 1 study is now enrolling patients into cohorts evaluating KVA12123 in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). The company will present additional scientific data in 2024 at an upcoming scientific meeting. SEATTLE, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (OTC:KANT) ("Kineta" or the "Company"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it has completed the enrollment of new patients into the monotherapy arm of the VI

      10/8/24 9:00:00 AM ET
      $KA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024

      SEATTLE, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (OTC:KANT) , a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that its abstract on the KVA12123 clinical program has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting to be held November 6-10, 2024, in Houston, Texas and virtually. Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, has announced that on November 8, 2024 Jason Henry M.D., Associate Director, Drug Development at Sarah Cannon Research Institute, Denver Colorado will be presenting the poster wi

      10/4/24 9:05:00 AM ET
      $KA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta's VISTA blocking antibody Currently in Phase 1

      TuHURA has extended their exclusivity and right of first offer pursuant to the terms of the agreement. Kineta and TuHURA are collaborating on the ongoing Phase 1/Phase 2 clinical trial in patients with advance solid tumor cancer SEATTLE, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (OTC:KANT) ("Kineta" or the "Company"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that TuHURA Biosciences Inc (TuHURA) is exercising its right to extend their exclusivity and right of first offer agreement (the "Agreement") for Kineta's VISTA blocking antibody KVA12123. Under the terms of the A

      10/2/24 4:05:00 PM ET
      $KA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Kineta Inc. (Amendment)

      SC 13D/A - KINETA, INC./DE (0001445283) (Subject)

      5/2/24 4:39:36 PM ET
      $KA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KA
    Leadership Updates

    Live Leadership Updates

    See more
    • Kineta Appoints Internationally-Renowned Clinical Immuno-oncology Experts to its Scientific Advisory Board

      SEATTLE, March 01, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on developing next-generation immunotherapies to address cancer immune resistance, announced today the appointment of Myriam Chalabi, M.D. and Evan Ya-Wen Yu, M.D. to the company's immuno-oncology focused Scientific Advisory Board (SAB). Dr. Chalabi and Dr. Yu will join Kineta's SAB that includes Lisa Coussens, Ph.D., Michael Curran, Ph.D. and Patricia LoRusso, D.O. to guide the clinical development of KVA12123, the company's VISTA blocking immunotherapy. "We are delighted to have Dr. Chalabi and Dr. Yu join Kineta's Scientific Advisory Board," stated Thierry Guillaudeux, P

      3/1/23 6:30:00 AM ET
      $KA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KA
    SEC Filings

    See more
    • Kineta Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - KINETA, INC./DE (0001445283) (Filer)

      10/2/24 4:07:07 PM ET
      $KA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kineta Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - KINETA, INC./DE (0001445283) (Filer)

      9/19/24 9:53:51 PM ET
      $KA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kineta Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - KINETA, INC./DE (0001445283) (Filer)

      9/19/24 9:21:01 AM ET
      $KA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Foote Marion R

      4 - KINETA, INC./DE (0001445283) (Issuer)

      9/5/24 4:20:49 PM ET
      $KA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Iadonato Shawn

      4 - KINETA, INC./DE (0001445283) (Issuer)

      9/5/24 4:21:14 PM ET
      $KA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Peters Richard

      4 - KINETA, INC./DE (0001445283) (Issuer)

      9/5/24 4:21:48 PM ET
      $KA
      Biotechnology: Pharmaceutical Preparations
      Health Care